Article
Search
231 Result(s)
Healthcare professionals
Boehringer Ingelheim Clinical Trials
Article
Taking Cancer On: Patient Podcast Episodes
Listen to our podcast episodes which feature people living with cancer and their perspectives on a range of cancer topics.
Clinical Studies
What are clinical trial lay summaries?
Learn what lay summaries are, how we produce them and why they are useful for patients and carers.
September 17, 2020
Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor
December 18, 2020
SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
July 26, 2021
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
September 16, 2021
Clinical collaboration with Amgen on KRAS
April 13, 2021
Phase 2 Clinical Testing in NASH and Obesity
October 29, 2019
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
September 04, 2019
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
September 10, 2020
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
October 28, 2020
Developing potential treatment for severe COVID19 complications
March 28, 2022
New spesolimab data show significant improvement in GPP flares
March 16, 2020
New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib
May 14, 2020
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
May 26, 2020
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction
Borderline Personality Disorder
Championing Novel Science
Dr. Vikas Mohan Sharma discusses the unmet need in Borderline Personality Disorder treatment and Boehringer Ingelheim’s role in research
Article
Drug Discovery
Find out more about the drug discovery process at Boehringer Ingelheim
COVID-19
Q&A for Patients with diabetes
Pulmonary Fibrosis
Facts about the INPULSIS™ trials
Media backgrounder
Patient Centricity
Our position
Boehringer Ingelheim’s position on compassionate use of investigational medications.
GPP
EADV: New frontiers in GPP
Dr. Emmanuelle Clerisme-Beaty reflects on the latest developments for generalized pustular psoriasis at this year’s virtual EADV congress
Article
“We do everything we can to help”
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Article
Answers for health care professionals and patients
Answers to common questions regarding Compassionate Use of experimental medications.